What Nuo Therapeutics does

Nuo Therapeutics, Inc. is a commercial-stage medical device company focused on regenerative therapies for chronic wound care. Its core technology is a biodynamic hematogel platform (Aurix) that leverages a patient's own platelets and plasma as a catalyst for healing chronic wounds, including diabetic foot ulcers and venous leg ulcers. The company also supplies the CENTRIO Platelet-Rich-Plasma System, which is marketed through an exclusive private-label distribution agreement with Smith+Nephew within its Advanced Wound Bioactives portfolio. Nuo's flagship therapy has demonstrated efficacy in two randomized controlled clinical trials and is supported by a CMS National Coverage Determination for diabetic patients effective April 2021, which has materially expanded reimbursement-driven demand.

The company generates revenue primarily through product sales of Aurix and related wound-care products, with Q1 2026 product revenue of approximately $1.22 million (up from $0.48 million in Q1 2025, a 169% year-over-year increase) and Q1 2026 total revenues of approximately $1.3 million. Its go-to-market is channel-led rather than direct: products are sold through Smith+Nephew in the US market and promoted at industry events such as the Symposium on Advanced Wound Care (SAWC). End customers are wound care specialists, hospitals, and clinics treating chronic exuding wounds, particularly diabetic patients with foot ulcers and venous leg ulcers who have not responded to conventional treatments.

Nuo Therapeutics is headquartered in Houston, Texas (8285 El Rio Street, Suite 190) and reports 11-50 employees. The company was founded in 1987 and has maintained a long operating history marked by multiple capital raises (including a 2014 $35M round led by Deerfield, a 2022 Form D exempt offering of $3.55M, and a 2026 $1.0M Loan and Security Agreement) and a prior acquisition of Aldagen in 2012. It remains in a net operating loss position (Q1 2026 net loss of $446K, improved from $745K), is investing in growth, and is moving toward breakeven operations.

Name

Nuo Therapeutics

Legal name

Nuo Therapeutics, Inc.

Website

https://nuot.com

Company type

Private

Founded year

1987

Operating status

Operating

Headcount range

11–50 employees

Short description

Nuo Therapeutics is a commercial-stage medical device company developing autologous platelet-rich-plasma biologics (Aurix and the CENTRIO PRP System) for chronic wound care, particularly diabetic foot ulcers and venous leg ulcers, distributed in the US through an exclusive private-label partnership with Smith+Nephew.

Ownership category

akta.pro rank

Product category

Regenerative Wound Care Medical Devices

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Platelet-Rich Plasma (PRP) & Blood-Derived Orthobiologics (HLAMANAB)

Keywords

• Wound care devices
• Regenerative therapies
• Platelet-rich plasma
• Biodynamic hematogel
• Autologous cell therapy

Headquarters

HQ city

Gaithersburg

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Product Sales (Aurix and related wound care products): Nuo Therapeutics generates revenue through the sale of its commercial-stage medical device products, primarily Aurix biodynamic hematogel for chronic wound care. Product revenues have shown strong growth, reaching $1.22 million in Q1 2026, up from $484,381 in Q1 2025. The company also benefits from Medicare reimbursement coverage for its products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Nuo Therapeutics is a commercial-stage medical device company that develops and markets biodynamic regenerative wound care products. Its flagship offering, Aurix, is a biodynamic hematogel derived from a patient's own platelets and plasma that catalyzes healing of chronic wounds such as diabetic foot ulcers and venous leg ulcers. Through an exclusive private label distribution agreement with Smith+Nephew, the company also markets the CENTRIO Platelet-Rich-Plasma (PRP) System for the same wound care indications.

Product overview

Nuo Therapeutics is a commercial-stage medical device company that offers a portfolio of regenerative wound care products. The flagship offering is Aurix, a biodynamic hematogel that uses a patient's own platelets and plasma to catalyze healing of chronic wounds. Additionally, through an exclusive private label distribution agreement with Smith+Nephew, the company markets the CENTRIO Platelet-Rich-Plasma System, which serves the same wound care indication. The portfolio centers on leveraging the body's own biological mechanisms for therapeutic benefit in chronic wound care.

Differentiator

Problem solved

Functional benefit

Brands

• Aurix: Biodynamic hematogel wound care product that uses a patient's own platelets and plasma as a catalyst for healing chronic wounds.

Products and services

• Aurix Biodynamic Hematogel A biodynamic hematogel derived from a patient's own platelets and plasma that catalyzes natural healing of chronic wounds including diabetic foot ulcers and venous leg ulcers. Targeted at healthcare providers, hospitals, and wound care clinics.
• CENTRIO Platelet-Rich-Plasma (PRP) System A biodynamic hematogel derived from a patient's own blood that aids natural wound healing for chronic exuding wounds including diabetic foot ulcers and venous leg ulcers. Marketed by Smith+Nephew through an exclusive private label agreement with Nuo Therapeutics. Validated in two randomized controlled clinical trials and covered by a CMS National Coverage Determination effective April 2021 for diabetic patients.

Quantifiable outcome

• 169% increase in Q1 2026 revenues compared to Q1 2025
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Smith+NephewcoreChannel Partner/ Reseller/ Distributor · 1 January 2026Smith+Nephew serves as the exclusive private label distribution partner for Nuo Therapeutics' wound care products including Aurix and the CENTRIO PRP System. Products are marketed through Smith+Nephew's Advanced Wound Bioactives portfolio. The partnership was formalized with the US launch of the CENTRIO Platelet-Rich-Plasma System at the Symposium on Advanced Wound Care Fall Conference.

Scale indicators6 records

Recent moves5 records

Expansion highlights3 records

Direct peers

• Organogenesis Holdings: Commercial-stage regenerative medicine company selling Apligraf and Dermagraft skin substitutes for chronic wounds (DFUs, VLUs, burns). Most direct comparable to Nuo in autologous/biologic wound-care products and reimbursement-driven commercial model.
• MiMedx Group: Regenerative medicine company marketing placental tissue allografts (e.g., EpiFix, AmnioFix) for chronic wound care and surgical applications — directly competing for the same wound-care providers and Medicare reimbursement dollars as Aurix.
• Vericel: Commercial-stage regenerative medicine company (MACI, Epicel) using autologous cell-based therapies in orthopedics and burn care — directly comparable business model of leveraging a patient's own biology in regulated, reimbursed clinical indications.

Broad incumbents

• Convatec Group: Global wound-care incumbent with a portfolio including advanced wound dressings, Avelle negative-pressure wound therapy, and InnovaMatrix placental tissue; competes across the same wound-care channels where Nuo distributes Aurix.
• Smith+Nephew: Global medical device company and Nuo's exclusive US private-label distributor; markets competing wound-care products (PICO, ALLEVYN, collagen-based substitutes) through the same Advanced Wound Management portfolio that carries Aurix/CENTRIO.
• Integra LifeSciences: Diversified surgical and regenerative tissue company selling Integra Dermal Regeneration Template and other wound/surgical repair products — comparable category and similar hospital/clinic customer base.
• Coloplast: Major wound and skin-care company with advanced wound dressings and skin substitutes (e.g., Biatain) sold to the same chronic-wound clinician base that Nuo targets with Aurix.
• 3M Health Care (Solventum): Following the Acelity spin/KCI integration, 3M/Solventum is a dominant wound-care incumbent with V.A.C. negative-pressure therapy and an extensive advanced wound portfolio overlapping Nuo's provider targets.

Emerging players

• Tissue Regenix Group: Smaller regenerative medicine company commercializing dCELL decellularized tissue products for wound care and orthopedics — comparable in scale and biologic, autologous-style mechanism, though currently focused on porcine-derived rather than platelet-based products.
• PolarityTE: Regenerative medicine company developing SkinTE and other autologous tissue products for chronic wounds and burns — comparable small-cap, autologous platform approach addressing a similar patient population as Aurix.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/cytomedix

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds16 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nuo Therapeutics